🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalCanadian GLP-1 coverage — provincial formulary comparison

Canadian GLP-1 coverage — provincial formulary comparison

CanadaChris Sun, Jun 7, 2026 at 12:16 PM 6 replies 128 viewsPage 1 of 2
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
Jun 7, 2026 at 12:16 PM#1

Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the talking.

What would genuinely help is knowing what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.

Practical detail welcome, however dull — the duller the better.

2 22Dr.EM_Chicago, pete_RVA
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jun 7, 2026 at 12:31 PM#2
CanadaChris said:
Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

Financial impact of cost and coverage weight loss beyond medication cost:

  • Groceries: SAVED $234/month (eating less)
  • Restaurants: SAVED $224/month (fewer meals out)
  • Alcohol: SAVED $174/month (stopped drinking)
  • Life insurance: Premium REDUCED by $44/month (lower BMI)
  • Copays: SAVED $64/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

Last edited: Jun 7, 2026 at 2:31 PM
1 21PharmD_Rodriguez
Reply Quote Save Share Report
AussieAnna
Member
678
2,890
Jun 2024
Sydney, AU
Jun 7, 2026 at 12:46 PM#3
LibrarianMeg said:
Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $234/month (eating less) Restaurants: SAVED $224/month…
LibrarianMeg said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Last edited: Jun 7, 2026 at 1:46 PM
50 20LibrarianMeg, bri_stats, pete_manc_UK and 47 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
fiona_glasgow
Member
312
1,345
Aug 2024
Glasgow, UK
Jun 7, 2026 at 1:01 PM#4
CanadaChris said:
Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

This is my experience too, for whatever a second data point is worth.

Last edited: Jun 7, 2026 at 6:01 PM
49 19JessicaH_TX, KevinCompounds, TirzTom and 46 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Jun 7, 2026 at 2:18 PM#5

From the other side of the consultation, briefly.

Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:

FeaturePlatform APlatform BPlatform C
Initial Consult$54$94$0
Monthly Follow-up$44Included$54
Prescription SpeedSame day24-48 hoursSame day
Lab MonitoringRequiredOptionalRequired

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

Last edited: Jun 7, 2026 at 4:18 PM
48 18Dr.ObesityLA, NurseKim_ATL, paul_denver and 45 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
UK Boots Wegovy availability — patient experience thread17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register